GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sirtex Medical Ltd (GREY:SRXTY) » Definitions » Return-on-Tangible-Equity

Sirtex Medical (Sirtex Medical) Return-on-Tangible-Equity : 26.03% (As of Jun. 2018)


View and export this data going back to 2015. Start your Free Trial

What is Sirtex Medical Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sirtex Medical's annualized net income for the quarter that ended in Jun. 2018 was $26.86 Mil. Sirtex Medical's average shareholder tangible equity for the quarter that ended in Jun. 2018 was $103.20 Mil. Therefore, Sirtex Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2018 was 26.03%.

The historical rank and industry rank for Sirtex Medical's Return-on-Tangible-Equity or its related term are showing as below:

SRXTY' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -20.95   Med: 33.92   Max: 61.53
Current: 30.13

During the past 13 years, Sirtex Medical's highest Return-on-Tangible-Equity was 61.53%. The lowest was -20.95%. And the median was 33.92%.

SRXTY's Return-on-Tangible-Equity is not ranked
in the Biotechnology industry.
Industry Median: -47.585 vs SRXTY: 30.13

Sirtex Medical Return-on-Tangible-Equity Historical Data

The historical data trend for Sirtex Medical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sirtex Medical Return-on-Tangible-Equity Chart

Sirtex Medical Annual Data
Trend Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.62 53.91 56.24 -21.15 28.38

Sirtex Medical Semi-Annual Data
Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.41 37.66 -76.40 36.16 26.03

Competitive Comparison of Sirtex Medical's Return-on-Tangible-Equity

For the Biotechnology subindustry, Sirtex Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sirtex Medical's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirtex Medical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Sirtex Medical's Return-on-Tangible-Equity falls into.



Sirtex Medical Return-on-Tangible-Equity Calculation

Sirtex Medical's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2018 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2018 )  (A: Jun. 2017 )(A: Jun. 2018 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2018 )  (A: Jun. 2017 )(A: Jun. 2018 )
=31.086/( (105.923+113.133 )/ 2 )
=31.086/109.528
=28.38 %

Sirtex Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2018 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jun. 2018 )  (Q: Dec. 2017 )(Q: Jun. 2018 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jun. 2018 )  (Q: Dec. 2017 )(Q: Jun. 2018 )
=26.86/( (93.272+113.133)/ 2 )
=26.86/103.2025
=26.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2018) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Sirtex Medical  (GREY:SRXTY) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Sirtex Medical Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Sirtex Medical's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Sirtex Medical (Sirtex Medical) Business Description

Traded in Other Exchanges
N/A
Address
Sirtex Medical is an Australian oncology-focused medical device company with a novel embolic radiation therapy device, which is currently used as salvage therapy in the treatment of inoperable liver cancer. Sirtex's key product is SIR-Spheres microspheres, which utilise extremely small resin beads containing radioactive yttrium-90. SIR-Spheres are designed, manufactured, and distributed by Sirtex for approved markets in Asia-Pacific; Europe, Middle East, and Africa, or EMEA; and North America.

Sirtex Medical (Sirtex Medical) Headlines

No Headlines